Jessica Ailani, AHS 2021: RELIEF Study – Rapid Resolution of Migraine Symptoms After Initiating Eptinezumab

It was a great pleasure to meet with Jessica Ailani (AHS Scientific Committee Member) (MedStar Georgetown Headache Center, Georgetown, WA, USA) to discuss the RELIEF study results.

The abstract ‘Rapid Resolution of Migraine Symptoms After Initiating the Preventive Treatment Eptinezumab During a Migraine Attack’ was presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting 2021, 3-6 June 2021.

Questions:

1. Could you tell us a little about the RELIEF study, its aims, design, inclusion criteria, clinical endpoints, and findings?
2. What were the findings in terms of associated migraine symptoms? (0:11)
3. What will be the focus on future research involving eptinezumab? (3:35)

Disclosures: Jessica Ailani receives honoraria for independent consulting from Amgen, Abbvie, Biohaven, Eli Lilly and Company, GlaxoSmithKline, Lundbeck, Teva, Impel, Satsuma, Axsome, Vorso, Aeon, Theranica, and Medscape; and has ownership of stocks in CtrM. Jessica Ailani is part of the Speakers Bureau and receives Honoraria for promotional speaking from Allergan/Abbvie, Amgen, Biohaven, Eli Lilly and Company, Lundbeck, and Teva. Jesscia Ailani also recevies honoraria for editorial services from Current Pain and Headache Reports, Section editor, Unusual Headache Syndromes, NeurologyLive, Infomedica (AHS Virtual Highlights 2020), and SELF (medical reviewer). Clinical Trial Grants: (Fees to Institution) American Migraine Foundation, Allergan/Abbvie, Biohaven, Eli Lilly and Company, Satsuma, and Zosano.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of AHS Virtual Annual Scientific Meeting 2021.